Helicobacter Pylori Clinical Trial
Official title:
Genotypes of Helicobacter Pylori in West African Children and Adults: Part 1: The Development and Evaluation of Minimally Invasive Techniques for Obtaining H. Pylori Isolates From Adults and Children in The Gambia
H. pylori infection causes the stomach to become inflamed. The problem usually begins in childhood and leads to stomach problems in adult life. Study participants will be residents of The Gambia, West Africa, and will be studied at the Medical Research Council of Great Britain facility in Fajara, The Gambia. Up to 75 adults 18 years and older and 20 malnourished children 6 months to 2 years of age, who are undergoing endoscopy as part of their medical care, will be studied. (Endoscopy is when a thin, lighted device is used to look inside the body.) During this study procedure, tiny pieces of tissue, called biopsies, will be taken from the stomach and checked for H. pylori infection. Participants found to be infected will be given antibiotic treatment. Participation in the study will last approximately 72 hours.
Status | Completed |
Enrollment | 75 |
Est. completion date | March 2009 |
Est. primary completion date | June 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 6 Months and older |
Eligibility |
Inclusion Criteria: Adult Subjects: All consenting subjects referred for diagnostic upper endoscopy to the Medical Research Council (MRC) unit in Fajara will be eligible for inclusion, provided none of the exclusion criteria apply. In The Gambia, subjects aged 18 years and above are considered as adult. Subjects will be sampled only once. Child Subjects: All subjects under 2 years of age referred for diagnostic upper endoscopy to the MRC unit in Fajara will be eligible for inclusion, provided their parents give informed consent and that none of the exclusion criteria apply. The minimum cut-off age for this study will be 6 months. Exclusion Criteria: Adult Subjects: Any contraindication to endoscopy and biopsy, such as as liver dysfunction, history of bleeding, history of other serious organ disease (for example, kidney, heart, lung), bleeding time prolonged to over 10 minutes, or unexpected findings such as esophageal or gastric stricture that limits endoscopic examination will exclude subjects from the study, as will the use of antibiotics during the previous 2 weeks. Specific tests such as bleeding times will be performed at the discretion of the supervising clinician, who is undertaking the diagnostic endoscopy for the subject's clinical benefit. In addition, if the endoscopist feels that prolonging the procedure by 2 or 3 minutes in order to take the research biopsies would not be advisable for any reason, the subject will be excluded from the study. Child Subjects: Any contraindication to endoscopy and biopsy, such as as liver dysfunction, history of bleeding, history of other serious organ disease (for example, kidney, heart, lung), bleeding time prolonged to over 10 minutes, or unexpected findings such as esophageal stricture that limits endoscopic examination will exclude subjects from the study, as will the use of antibiotics during the previous 2 weeks. In addition, if the endoscopist feels that prolonging the procedure by 2 or 3 minutes in order to take the research biopsies would not be advisable for any reason, the subject will be excluded from the study. Specific tests such as bleeding times will be performed at the discretion of the supervising clinician, who is undertaking the diagnostic endoscopy for the subject's clinical benefit. |
Observational Model: Case-Only, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Gambia | Medical Research Council's Laboratories | Banjul |
Lead Sponsor | Collaborator |
---|---|
Medical Research Council Unit, The Gambia | National Institute of Allergy and Infectious Diseases (NIAID) |
Gambia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The degree of relatedness between bacterial isolates | This will be assessed by visual comparison between RAPD results, by comparison of genotypes for alleles of interest, and definitively by sequencing of housekeeping genes to construct phylogenetic trees of relatedness, using the STAR program (a computer program for putting DNA sequences together for analysis) and MLST database. There are no outcome measures for human subjects. All laboratory investigations will be conducted upon bacterial isolates There are no outcome measures for human subjects. All laboratory investigations will be conducted upon bacterial isolates |
4 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02892409 -
TAK-438 Bismuth Drug Interaction Study
|
Phase 1 | |
Completed |
NCT05073367 -
A Study Reviewing Medical Records of Adults With Helicobacter Pylori Infections in China
|
||
Completed |
NCT00596401 -
The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer
|
||
Not yet recruiting |
NCT04101708 -
A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for H.P Eradication in Elderly Patients
|
Phase 4 | |
Recruiting |
NCT04030715 -
The Associations Between the Gastric Mucosal Pathology and the Eradication Rate of H.Pylori :A Multicenter Study
|
N/A | |
Recruiting |
NCT04029415 -
The Study of the Antimicrobial Resistance of Helicobacter Pylori in Shandong Province
|
||
Recruiting |
NCT04029493 -
The Situation of Re-infection of Helicobacter Pylori After Successful Eradication
|
||
Not yet recruiting |
NCT02934048 -
Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection
|
Phase 4 | |
Not yet recruiting |
NCT02933229 -
The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study
|
Phase 4 | |
Recruiting |
NCT05184491 -
Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management
|
Phase 4 | |
Recruiting |
NCT05790525 -
Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy
|
Phase 4 | |
Completed |
NCT05790512 -
Association of Oral Helicobacter Pylori Infection With Gastric Helicobacter Pylori Infection
|
||
Recruiting |
NCT05276557 -
PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study
|
Phase 3 | |
Recruiting |
NCT03177629 -
H. Pylori Eradication for Moderate ITP
|
Phase 3 | |
Recruiting |
NCT05053945 -
Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study
|
||
Recruiting |
NCT05449028 -
Helicobacter Pylori Eradication Therapy in Portugal
|
N/A | |
Recruiting |
NCT00306280 -
Feasibility Study of Phototherapy System to Treat H Pylori
|
N/A | |
Active, not recruiting |
NCT02675010 -
Value of Additional Corpus Biopsy for Diagnosis of H Pylori in Atrophic Gastritis. Prospective Non-randomized Study
|
N/A | |
Withdrawn |
NCT00467155 -
Helicobacter in The Gambia (Part 2)
|
N/A | |
Completed |
NCT03716622 -
A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication
|
Phase 4 |